0001650664-26-000045
SEC filingEditas Medicine's Q1 2026 revenue declined sharply, but operating losses narrowed significantly due to cost restructuring, while cash burn improved.
Revenue for Q1 2026 was $2.8 million, a decrease of 39% compared to $4.7 million in Q1 2025. The decline is attributable to reductions in investment income due to a decrease in our investments for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.
Operating loss improved 67% to -$25.0 million from -$76.2 million in the prior year, reflecting significant cost restructuring. Net loss improved similarly to -$25.0 million from -$76.1 million, with diluted EPS improving to -$0.26 from -$0.92. The improvement was driven by reductions in research and development expenses and general and administrative expenses, as we continue to focus on operational efficiency. We expect research and development expenses to increase in future periods to support EDIT-401 preclinical activities and to fund our clinical trials.
We anticipate that our general and administrative expenses that support continued research and development activities will remain consistent in the near future. We expect to continue to incur significant expenses and operating losses for the foreseeable future. In addition, even if we successfully identify and develop product candidates that are approved, we will require significant additional funding in order to launch and commercialize our product candidates and may not achieve commercial success.